The Print on MSN
Centre’s trade margin cap for cancer drugs has its limits. Not all 137 listed meds may become affordable
India’s new cancer drug price cap promises major savings, but it does not directly control manufacturers’ starting prices, leaving costly patented medicines beyond many patients’ reach.
The influx of novel therapies is expanding treatment options for patients with cancer, but distance, infrastructure, and ...
Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in ...
KEYTRUDA as Monotherapy Reduced Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent ...
The FDA grants traditional approval to Keytruda and Keytruda Qlex for TMB-H solid tumors, updating the threshold to at least ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination ...
The approval covers IV and subcutaneous pembrolizumab and raises the TMB-H threshold from 10 to 13 mutations/megabase.
Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...
Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected ...
Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the ...
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining ...
A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results